14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
PHVS vs NTLA: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Pharvaris N.V. (PHVS) is the stronger overall head-to-head candidate over Intellia Therapeutics, Inc (NTLA) in the Tradestie Institutional Equity Comparison Engine, winning 5–2 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). PHVS carries a Unified Composite Score of 37.6/100 (SELL) at $32.61 (N/M Forward P/E, 0.0% operating margin), whereas NTLA carries 50.7/100 (HOLD) at $10.00 (N/M Forward P/E, -826.0% operating margin).
Composite vs. Pillar Nuance: While NTLA currently prints a higher short-term Unified Composite Score (50.7/100 HOLD vs. PHVS 37.6/100 SELL), PHVS captures the overall institutional head-to-head verdict (5–2 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -826.0% operating margin) and revenue trajectory (+0.0% vs. -48.0% YoY).
Technical & Structure Timing Caution: PHVS is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 47.7); meanwhile NTLA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on PHVS vs NTLA. Trailing 12-month operating profitability (PHVS 0.0% vs NTLA -826.0%) and valuation multiples (PHVS N/M vs NTLA N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $1.5B market capitalization and -826.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published · CRISPR / Gene Editing
Investor FAQ PHVS vs NTLA Key Questions & Quantitative Answers
As of Nov 16, 2026, Pharvaris N.V. (PHVS) is the stronger overall head-to-head candidate over Intellia Therapeutics, Inc (NTLA) in the Tradestie Institutional Equity Comparison Engine, winning 5–2 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). PHVS carries a Unified Composite Score of 37.6/100 (SELL) at $32.61 (N/M Forward P/E, 0.0% operating margin), whereas NTLA carries 50.7/100 (HOLD) at $10.00 (N/M Forward P/E, -826.0% operating margin). Composite vs. Pillar Nuance: While NTLA currently prints a higher short-term Unified Composite Score (50.7/100 HOLD vs. PHVS 37.6/100 SELL), PHVS captures the overall institutional head-to-head verdict (5–2 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -826.0% operating margin) and revenue trajectory (+0.0% vs. -48.0% YoY). Technical & Structure Timing Caution: PHVS is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 47.7); meanwhile NTLA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
PHVS leads the Growth & Scale pillar: PHVS posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with NTLA at -48.0% YoY revenue growth and +0.0% YoY earnings growth on $53M TTM revenue (N/A gross margin, -826.0% operating margin). On trailing 12-month operating scale, PHVS generates N/A in USD-normalized revenue versus $53M for NTLA. In operating R&D and SG&A reinvestment, PHVS deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for NTLA.
NTLA screens cheaper on headline valuation multiples. PHVS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas NTLA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 29.1x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PHVS (-70.5% ROE) versus NTLA (-62.6% ROE) capital efficiency.
In options market volatility and institutional positioning, PHVS carries 81.1% implied volatility (7th %ile, Compressed (<25th %ile)), a 1.15x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.67β · 38% Vol realized risk). By comparison, NTLA carries 101.3% implied volatility (78th %ile, Elevated (60th–80th %ile)), a 0.42x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.30β · 87% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.